Monday (28.10.2024)

08:00 – 09:00

Room: Großer Saal

Scientific Session Special Situations & Cases

  • Alexander Fosså
  • Anna Sureda

  • Treatment Approaches in Ressource Constraint Settings

    • Chite Asirwa
    • Otavio Baiocchi

  • HL Richter Transformation Pathologists perspective

    • Sylvia Hartmann

  • HL Richter Transformation HL perspective

    • Mark Hertzberg

  • HL Richter Transformation CLL perspective

    • Othman Al-Sawaf

09:15 – 10:15

Room: Großer Saal

Scientific Session NLPHL

  • Richard Hoppe
  • Wolfram Klapper
  • 09:15–09:35

    NLPHL: HL, NHL or something else?

    • Sylvia Hartmann
  • 09:35–09:55

    First-line treatment of NLPHL with HL-directed approaches

    • Dennis Eichenauer
  • 09:55–10:15

    Treatment of NLPHL with NHL-directed approaches

    • Graham Collins
  • 10:15–10:20

    Q&A

    • Graham Collins
    • Eichenauer Dennis
    • Sylvia Hartmann

10:30 – 12:00

Room: Großer Saal

Scientific Session Living Beyond Lymphoma

  • John Radford
  • Flora van Leeuwen
  • 10:30–10:50

    Late consequences of drugs used in the modern era of treatment for HL (to include anthracyclines, bleomycin, checkpoint inhibitors, ADCs)

    • Stephen Ansell
  • 10:50–11:10

    Starting Living beyond Lymphoma with HL diagnosis

    • Karolin Behringer
    • Maximilian Büttner
  • 11:10–11:30

    Participation in and (cost-)effectiveness of the Dutch HL survivorship care program

    • Berthe Aleman
    • Annelies Nijdam
  • 11:30–11:40

    A priori estimation of mediastinal toxicities after radiotherapy for Hodgkin Lymphoma - A secondary analysis of the HD16/17 Trial by the German Hodgkin Study Group using normal tissue complication probability calculations

    • Michael Oertel
  • 11:40–11:50

    Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials

    • Sidsel Juul
  • 11:50–12:00

    Novel 3D speckel tracking imaging modality in detecting cardiac toxicity in asymptomatic pediatric HL survivors

    • Zeinab Salah Seliem

12:30 – 14:00

Room: Großer Saal

Scientific Session Relapsed & Refractory HL

  • Philippe Armand
  • Craig H. Moskowitz
  • 12:30–12:50

    Updated approach to second-line treatment

    • Alison Moskowitz
  • 12:50–13:10

    Emerging strategies to overcome anti-PD1 resistance

    • Stephen Ansell
  • 13:10–13:30

    Implementing raditoherapeutic concepts in rrHL care

    • Christian Baues
  • 13:30–13:40

    Brentuximab Vedotin - ESHAP Significantly Increases the Metabolic Complete Remission Rate versus ESHAP in Relapsed Classical Hodgkin’s Lymphoma. Final Results of the BRESELIBET Prospective Trial.

    • Anna Sureda
  • 13:40–13:50

    Longitudinal circulating tumor DNA sequencing may predict the response to PD1 blockade therapy in relapsed/refractory classical Hodgkin Lymphoma patients

    • Francesco Corrado
  • 13:50–14:00

    Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin

    • Alison Moskowitz

14:00

Room: Großer Saal

Main Program Closing remarks

  • Ranjana Advani
  • Sally Barrington
  • Sven Borchmann
  • Carsten Kobe
  • Wouter Plattel
  • 14:00–14:25

    Workshop Report

    • Sally Barrington
    • Sven Borchmann
    • Carsten Kobe
    • Wouter Plattel
    • Davide Rossi
  • 14:25–14:45

    Best of ISHL13

    • Ranjana Advani

  • Farewell

    • Peter Borchmann

ISHL13 Program at a Glance (PDF)

ISHL13 Program at a Glance (PDF)

ISHL13 Final Program

ISHL13 Final Program

Save the date

Save the event to your calendar

Archive

You can explore the ISHL12 program to get an impression of the broad spectrum and diversity of the congress.